Research into human stem cell research is not to be banned but handled with caution, says the European Group on Ethics in Science and New Technologies

Brussels, 15/11/2000 (Agence Europe) - While recongising the major interest of research into human stem cells and its apparently very promising therapeutic prospects, the European Group on Ethics in Science and New Technologies (EGE), chaired by Noelle Lenoir, urges the European Union to be cautious. In its opinion on the ethical aspects of human stem cell research and use, the EGE considers that "at present, the creation of embryos by somatic cell nuclear transfer ("therapeutic cloning") for research on stem cell therapy would be premature, since there is a wide field of research to be carried out with alternative sources of human stem cells: from spare embryos, foetal tissues and adult stem cells".

Consequently, the Group recommends:

• A specific Community budget for research on these alternative sources, especially adult stem cells, be provided;
• Ensure, at Union level, that "the results of such research be widely disseminated, and not hidden for reasons of commercial interest";
• An ethical assessment of research on stem cells financed by Community appropriations be carried out both "before the launching of a project and in monitoring its implementation";
• It be ensured that "the demand for spare embryos and oocyte donation does not increase the burden on women" undergoing fertility treatment"

Regarding the use of stem cells in clinical testing, the Group stresses the need for safety and protection of the health of the patients. It mentions the "risk that transplanted stem cells could cause abnormalities or induce the creation of cancerous tumours" and stresses that "it is important that the potential benefits for the patients should be taken into account but not exaggerated".